JOURNAL OF CRITICAL REVIEWS

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

GIGANTIC INFLUENCES HORMONE IMBALANCES, PITUITARY ADENOMA, GENETIC MUTATIONS AND SYMPTOMS, DIAGNOSIS, DIFFERENTIAL DIAGNOSIS AS WELL AS TREATMENT OF GIGANTISM

Vikunta Rao. V[1] Muralinath E.[1] , Manjari P.[1] , Sravani Pragna K.[1] , Kalyan C.[1] Guru Prasad M[2] , Venkat Navven. A[3] , Sravani. K.[4] ,Sony Sharlet. E[5]

[1]College of Veterinary Science, Proddatur, Andhra Pradesh, India.
[2]Vaishnavi Microbial Phama Pvt. Ltd, Hyderabad, India
[3]Technical Sales Officer, Vijayawada, Andhra Pradesh, India
[4]Veterinary Officer, Nuzivedu, Andhra Pradesh, India
[5]Veterinary College, Tirupati, Andhra Pradesh, India

ABSTRACT:-

Gigantism is a rare endocrine disorder manifested by excessive growth in children and adolescents due to an iverproduction of growth hormone. Genetic mutations also lead to gigantism. Symptoms include facial changes. Large habds as well feet, nuscle weakness, cardio vascular issues, joint problems. Diagnosis involves measurimg the level of GH and IGF-1. Treatment concludes surgical reboval of the tumor, medications, long-term follow-Up as well as hormone replacement treatment (HRT).

KEY WORDS:- Adolescents, growth hormone, adenoma, genetic mutations, tumor, jhoint issues, enllkarged jaw, thickening of nose, cardiomegaly, osteoarthritis, headaches, vision problems, ernlartged spleen as well as liver, MRI scan, organomegaly, Trans sphenoidal surgery, somatostatin analogs and hormone replace therapy.

Introduction

Gigantism is a rare endocrine disorder characterized by excessive growth in children and adolescents due to an overproduction of growth hormone (GH). This condition leads to abnormal height and various health complications. In this article, we will delve into the clinical aspects of gigantism, exploring its causes, symptoms, diagnosis, and treatment.



ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Causes of Gigantism

1.Hormonal Imbalance:

Gigantism primarily results from an overproduction of growth hormone (GH) by the pituitary gland. This excessive GH secretion often occurs due to a tumor or adenoma in the pituitary gland, known as a pituitary adenoma. These tumors stimulate the gland to release GH uncontrollably.

2.Pituitary Adenoma

Definition: Pituitary adenomas are benign tumors of the pituitary gland.

Cause: Most cases of gigantism result from a pituitary adenoma that produces excess GH.

Mechanism: The tumor stimulates the pituitary gland to produce an abundance of GH, leading to excessive growth.

3.Genetic Mutations

Definition: Rare genetic mutations can cause gigantism.

Cause: Inherited genetic mutations affecting genes related to GH regulation.

Mechanism: These mutations disrupt normal GH regulation, causing uncontrolled growth.

4.McCune-Albright Syndrome

Definition: McCune-Albright syndrome is a genetic disorder.

Cause: Activating mutations in the GNAS1 gene.

Mechanism: These mutations lead to an overproduction of GH, causing gigantism as one of the symptoms.

5.Carney Complex

Definition: Carney complex is a rare genetic disorder.

Cause: Genetic mutations, often in the PRKAR1A gene.

Mechanism: These mutations can lead to excessive GH secretion and gigantism.

6.Ectopic GH Secretion

Definition: Rare cases involve tumors outside the pituitary gland.

Cause: Tumors in other parts of the body can produce GH.

Mechanism: These tumors release GH, leading to gigantism.

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

7.Rare Syndromes

Definition: Gigantism can be associated with certain syndromes.

Cause: Syndromes like Sotos syndrome or Beckwith-Wiedemann syndrome may involve excessive growth.

Mechanism: Altered genetic regulation within these syndromes can lead to gigantism as a feature.

8.Unknown Causes

Definition: In some cases, the exact cause of gigantism remains unknown.

Cause: Despite extensive testing, no specific genetic or tumor-related cause can be identified.

Mechanism: It is a challenging subset to diagnose and manage.

9.Complication

Definition: Gigantism can lead to various health issues.

Cause: Excessive GH can affect multiple organs and systems.

Mechanism: Complications may include cardiovascular problems, joint issues, and metabolic abnormalities.

Symptoms of Gigantism

Excessive Growth:

The hallmark symptom of gigantism is excessive height. Affected individuals often grow much taller than their peers. This accelerated growth typically begins in childhood and continues until the growth plates in the bones close.

Facial Changes:

Gigantism can lead to distinct facial changes, including an enlarged jaw (prognathism) and thickening of the nose and lips. This can result in a coarser facial appearance.

Large Hands and Feet:

Hands and feet may also enlarge significantly. This can cause difficulties in finding appropriately sized footwear and gloves.

Muscle Weakness:

Excessive growth can strain muscles, leading to muscle weakness and reduced physical endurance.

Cardiovascular Issues:

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Gigantism can increase the risk of cardiovascular problems such as hypertension and cardiomegaly (enlarged heart).

Joint Problems:

The rapid growth can put stress on joints, leading to joint pain and osteoarthritis.

Headaches and Vision Problems:

The pituitary adenoma responsible for gigantism may cause headaches and vision problems due to its proximity to the optic nerve.

Thickened Skin

Skin may thicken and become coarse.

Enlarged Organs

Internal organs may also enlarge, leading to complications.

Enlarged heart can result in cardiovascular issues.

Enlarged liver and spleen may cause abdominal discomfort

Diagnosis of Gigantism

Hormone Testing:

The initial step in diagnosing gigantism is hormone testing. This involves measuring the levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in the blood. Elevated GH and IGF-1 levels are indicative of gigantism.

Imaging:

Imaging studies such as MRI or CT scans are performed to locate and assess the size of the pituitary adenoma responsible for the excess GH production.

Genetic Testing:

In some cases, genetic testing may be necessary to rule out genetic causes of excessive growth.

Differential diagnosis of Gigantism

Growth Hormone-Producing Pituitary Adenoma (Acromegaly):

Elevated levels of insulin-like growth factor 1 (IGF-1).

Symptoms of acral overgrowth (enlarged hands and feet), coarsened facial features, and organomegaly.

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Pituitary Gigantism:

Typically occurs in children or adolescents due to excessive growth hormone secretion.

Rapid linear growth, delayed puberty, and enlarged features.

McCune-Albright Syndrome:

Associated with café-au-lait spots, polyostotic fibrous dysplasia, and precocious puberty.

Gigantism-like growth patterns in some cases.

Multiple Endocrine Neoplasia Type 1 (MEN1):

May present with pituitary adenomas causing gigantism.

Associated with other endocrine tumors (parathyroid, pancreatic).

Carney Complex:

May involve pituitary adenomas leading to gigantism.

Often associated with cardiac and cutaneous myxomas.

Non-Pituitary Tumors:

Rarely, gigantism can result from non-pituitary tumors, such as lung or pancreatic tumors, secreting growth hormone-releasing hormone (GHRH).

Primary Hypothyroidism:

Severe and untreated hypothyroidism in children can cause excessive linear growth.

Genetic Syndromes:

Marfan syndrome, Sotos syndrome, and Beckwith-Wiedemann syndrome may exhibit gigantism-like features.

Exogenous Hormone Exposure:

Gigantism can occur in cases of excessive use of growth hormone or anabolic steroids.

Rare Genetic Disorders:

Conditions like Weaver syndrome or Simpson-Golabi-Behmel syndrome can cause overgrowth.

Isolated Growth Hormone Deficiency:

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Rarely, gigantism-like features can occur if there's a deficiency of factors inhibiting growth hormone release.

Psychosocial Factors:

Gigantism-like appearance can result from psychological issues causing exaggerated concern about one's height.

Treatment of Gigantism

Surgical Removal of the Tumor:

The primary treatment for gigantism is the surgical removal of the pituitary adenoma. This procedure is known as transsphenoidal surgery. It aims to remove the tumor while preserving normal pituitary function.

Medications:

In some cases, medications like somatostatin analogs or growth hormone receptor antagonists may be used to lower GH levels before surgery or if surgery is not possible.

Radiation Therapy:

Radiation therapy may be considered when surgery and medication are ineffective or not feasible.

Multidisciplinary Care:

A team of specialists, including endocrinologists, neurosurgeons, and radiologists, is often involved in the treatment plan.

Psychological support and counseling may be necessary for patients dealing with the emotional and social challenges of gigantism.

Long-Term Follow-Up:

Regular follow-up appointments are essential to monitor hormone levels, growth, and potential complications.

Treatment adjustments may be needed as the patient's condition evolves.

Potential Complications:

Gigantism can lead to various health issues, including cardiovascular problems, joint pain, and diabetes.

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Treating and managing these complications is an integral part of the overall treatment plan.

Patient Education:

Educating patients and their families about the condition, treatment options, and potential side effects is vital for informed decision-making.

Hormone Replacement Therapy:

After successful treatment, some patients may require hormone replacement therapy to address deficiencies caused by the treatment.

Support Groups and Resources:

Encourage patients to connect with support groups and organizations dedicated to rare conditions like gigantism for emotional and informational support.

Conclusion

Gigantism is a rare condition with significant clinical implications. Early diagnosis and appropriate treatment are crucial to manage its symptoms and prevent complications. With advances in medical science, individuals with gigantism can receive effective treatment and lead healthier lives. Awareness of this condition is essential among healthcare professionals and the general public to ensure timely intervention and support for affected individuals.

REFERENCES AND FURTHER READING:-

· *Dorland's Medical Dictionary*
· "Gigantism | UCLA Pituitary Tumor Program". *pituitary.ucla.edu*. Retrieved 27 April 2017.
· · "Gigantism: MedlinePlus Medical Encyclopedia". *medlineplus.gov*. Retrieved 27 April 2017.
· · "Gigantism and Acromegaly: Practice Essentials, Background, Pathophysiology and Etiology". *7 January 2017.*
· · "Gigantism and Acromegaly – Hormonal and Metabolic Disorders – MSD Manual Consumer Version". *MSD Manual Consumer Version*. Retrieved 27 April 2017.
· · *Rostomyan, Liliya; Daly, Adrian F.; Petrossians, Patrick; Nachev, Emil; Lila, Anurag R.; Lecoq, Anne-Lise; Lecumberri, Beatriz; Trivellin, Giampaolo; Salvatori, Roberto (October 2015).* "Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients". *Endocrine-Related Cancer.* ***22*** *(5): 745–757.* doi:10.1530/ERC-15-0320. ISSN 1479-6821. PMC 6533620. PMID 26187128.
· · *Rostomyan, Liliya; Potorac, Iulia; Beckers, Pablo; Daly, Adrian F.; Beckers, Albert (2017). "AIP mutations and gigantism". Annales d'Endocrinologie.* ***78*** *(2): 123–130.* doi:10.1016/j.ando.2017.04.012. PMID 28483363.
· · *Chanson, Philippe; Salenave, Sylvie (25 June 2008).* "Acromegaly". *Orphanet Journal of Rare Diseases.* ***3****: 17.* doi:10.1186/1750-1172-3-17. ISSN 1750-1172. PMC 2459162. PMID 18578866.

· · *Capatina, Cristina; Wass, John A. H. (August 2015).* "60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly". *The Journal of Endocrinology.* ***226*** *(2): T141–160.* doi:10.1530/JOE-15-0109. ISSN 1479-6805. PMID 26136383.
· · *Zimmerman, D; Young, W F; Ebersold, M J; Scheithauer, B W; Kovacs, K; Horvath, E; Whitaker, M D; Eberhardt, N L; Downs, T R (1 January 1993). "Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation". The Journal of Clinical Endocrinology & Metabolism.* ***76*** *(1): 216–222.* doi:10.1210/jcem.76.1.8421089. ISSN 0021-972X. PMID 8421089.
· · *Eugster, Erica A.; Pescovitz, Ora H. (1 December 1999).* "Gigantism". *The Journal of Clinical Endocrinology & Metabolism.* ***84*** *(12): 4379–4384.* doi:10.1210/jcem.84.12.6222. ISSN 0021-972X. PMID 10599691.
· · *Murray, P. G.; Clayton, P. E. (2000).* "Disorders of Growth Hormone in Childhood". *In De Groot, Leslie J.; Chrousos, George; Dungan, Kathleen; Feingold, Kenneth R.; Grossman, Ashley; Hershman, Jerome M.; Koch, Christian; Korbonits, Márta; McLachlan, Robert (eds.). Endotext. South Dartmouth (MA): MDText.com, Inc.* PMID 25905205.
· · *Shim, Kye Shik (March 2015).* "Pubertal growth and epiphyseal fusion". *Annals of Pediatric Endocrinology & Metabolism.* ***20*** *(1): 8–12.* doi:10.6065/apem.2015.20.1.8. ISSN 2287-1012. PMC 4397276. PMID 25883921.
· · *Laron, Z (October 2001).* "Insulin-like growth factor 1 (IGF-1): a growth hormone". *Molecular Pathology.* ***54*** *(5): 311–316.* doi:10.1136/mp.54.5.311. ISSN 1366-8714. PMC 1187088. PMID 11577173.
· · *Lupu, Floria; Terwilliger, Joseph D.; Lee, Kaechoong; Segre, Gino V.; Efstratiadis, Argiris (2001).* "Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth". *Developmental Biology.* ***229*** *(1): 141–162.* doi:10.1006/dbio.2000.9975. PMID 11133160.
· · *Sanders, Esmond J.; Harvey, Steve (2004). "Growth hormone as an early embryonic growth and differentiation factor". Anatomy and Embryology.* ***209*** *(1): 1–9.* doi:10.1007/s00429-004-0422-1. PMID 15480774. S2CID 19528310.
· · De Mais, Daniel. ASCP Quick Compendium of Clinical Pathology, 2nd Ed. ASCP Press, Chicago, 2009.
· · *Trivellin, Giampaolo; Daly, Adrian F.; Faucz, Fabio R.; Yuan, Bo; Rostomyan, Liliya; Larco, Darwin O.; Schernthaner-Reiter, Marie Helene; Szarek, Eva; Leal, Letícia F. (2014).* "Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation". *New England Journal of Medicine.* ***371*** *(25): 2363–2374.* doi:10.1056/nejmoa1408028. PMC 4291174. PMID 25470569.
· · *Beckers, Albert; Aaltonen, Lauri A.; Daly, Adrian F.; Karhu, Auli (1 April 2013).* "Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene". *Endocrine Reviews.* ***34*** *(2): 239–277.* doi:10.1210/er.2012-1013. ISSN 0163-769X. PMC 3610678. PMID 23371967.
· · *Vierimaa, Outi; Georgitsi, Marianthi; Lehtonen, Rainer; Vahteristo, Pia; Kokko, Antti; Raitila, Anniina; Tuppurainen, Karoliina; Ebeling, Tapani M. L.; Salmela, Pasi I. (26 May 2006). "Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene". Science.* ***312*** *(5777): 1228–1230.* Bibcode:2006Sci...312.1228V. doi:10.1126/science.1126100. ISSN 0036-8075. PMID 16728643. S2CID 37013760.
· · *Rostomyan, Liliya; Daly, Adrian F.; Beckers, Albert (2015). "Pituitary gigantism: Causes and clinical characteristics". Annales d'Endocrinologie.* ***76*** *(6): 643–649.* doi:10.1016/j.ando.2015.10.002. PMID 26585365.
· · *Goldenberg, Naila; Racine, Michael S.; Thomas, Pamela; Degnan, Bernard; Chandler, William; Barkan, Ariel (1 August 2008).* "Treatment of Pituitary Gigantism with the Growth Hormone Receptor Antagonist Pegvisomant". *The Journal of Clinical Endocrinology & Metabolism.* ***93*** *(8): 2953–2956.* doi:10.1210/jc.2007-2283. ISSN 0021-972X. PMC 2515082. PMID 18492755.

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

· · *Rix, M.; Laurberg, P.; Hoejberg, A. S.; Brock-Jacobsen, B. (1 August 2005).* "Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl". *European Journal of Endocrinology*. ***153*** *(2): 195–201.* doi:10.1530/eje.1.01956. ISSN 0804-4643. PMID 16061823.
· · "Gigantism". *Question.com. Archived from* the original *on 13 March 2012*. Retrieved 14 March 2012.
· In a Giant's Story, a New Chapter Writ by His DNA – By Gina Kolata. The New York Times, January 5, 2011